Clinical neuroscientist Joe Schacht offered an overview of the research on weight-loss drugs for alcoholism, other potential ...

The vast majority of people who have a substance use disorder (SUD) never seek treatment. At most, 10% of adults with a drug or alcohol use disorder have entered any type of inpatient or outpatient ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

New research suggests semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, could help people reduce their alcohol consumption.

When we reframe how we view opioid and substance use, we can begin to engage in more evidence-based policies that are approached with compassion.

Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...

A new clinical trial showed promising results in curbing alcohol cravings in individuals with moderate alcohol-use disorder.

In Wednesday’s Health headlines, a link between gut bacteria and multiple sclerosis, new research on stress and cancer and ...

Australians will wait an average of 12 years before getting treatment for mental health or substance use disorders, according ...

Semaglutide, known as Ozempic, may reduce alcohol cravings and consumption, offering new addiction treatment possibilities.

A breakthrough study reveals that semaglutide, found in Ozempic and Wegovy, could help reduce alcohol cravings and heavy ...